TY  - GEN
AU  - Atzpodien,J
AU  - Kirchner,H
AU  - Rebmann,U
AU  - Soder,M
AU  - Gertenbach,U
AU  - Siebels,M
AU  - Roigas,J
AU  - Raschke,R
AU  - Salm,S
AU  - Schwindl,B
AU  - Müller,S C
AU  - Hauser,S
AU  - Leiber,C
AU  - Huland,E
AU  - Heinzer,H
AU  - Siemer,S
AU  - Metzner,B
AU  - Heynemann,H
AU  - Fornara,P
AU  - Reitz,M
TI  - Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
SN  - 0007-0920
PY  - 2006///0915
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Capecitabine
KW  - Carcinoma, Renal Cell
KW  - drug therapy
KW  - Deoxycytidine
KW  - administration & dosage
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Germany
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Interleukin-2
KW  - Isotretinoin
KW  - Kidney Neoplasms
KW  - Lung Neoplasms
KW  - secondary
KW  - Male
KW  - Middle Aged
KW  - Recombinant Proteins
KW  - Survival Analysis
N1  - Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/sj.bjc.6603271
ER  -